跳至主要内容
临床试验/EUCTR2010-024049-53-GB
EUCTR2010-024049-53-GB进行中(未招募)不适用

Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes - onset® 1

ovo Nordisk A/S0 个研究点目标入组 1,095 人开始时间: 2013年5月30日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
1,095

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Female or male, age 18 years or older at the time of screening (Visit 1)
  • Type 1 diabetes (diagnosed clinically) for 12 months or longer at the time of screening (Visit 1)
  • Currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1)
  • Currently treated with a basal insulin analogue (any regimen of insulin detemir or insulin glargine) for at least 4 months prior to screening (Visit 1)
  • HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory
  • Body Mass Index (BMI) equal to or below 35.0 kg/m^2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 602
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 493

排除标准

  • Use of any anti-diabetic drug other than insulin within the last 3 months prior to screening (Visit 1)
  • Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening (Visit 1)
  • Cardiovascular disease, within the last 6 months prior to screening (Visit 1), defined as stroke, decompensated heart failure New York Heart Association (NYHA) class III or IV, myocardial infarction, unstable angina pectoris, coronary arterial bypass graft or angioplasty

研究者

相似试验

进行中(未招募)
不适用
Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 DiabetesMedDRA version: 14.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1
EUCTR2010-024049-53-HUovo Nordisk A/S1,095
进行中(未招募)
不适用
Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 DiabetesDiabetes Mellitus, Type 1
EUCTR2010-024049-53-PLovo Nordisk A/S1,095
进行中(未招募)
不适用
Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 DiabetesMedDRA version: 18.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1
EUCTR2010-024049-53-CZovo Nordisk A/S1,095
进行中(未招募)
不适用
Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 DiabetesMedDRA version: 18.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Diabetes Mellitus, Type 1
EUCTR2010-024049-53-FIovo Nordisk A/S1,095
进行中(未招募)
1 期
Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 DiabetesDiabetes Mellitus, Type 1MedDRA version: 17.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861
EUCTR2010-024049-53-DEovo Nordisk A/S1,095